

MD Anderson at the San Antonio Breast Cancer Symposium



December 10-14, 2019

Henry B. González Convention Center | San Antonio, TX

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center
Making Cancer History®

P R E S E N T A T I O N S

Tuesday, Dec. 10

2-3:30 p.m.	Workshop: Evolving Opportunities to Personalize Radiation Decisions	<i>Guiding selection of RT approach after lumpectomy</i>	Simona Shaitelman, M.D.	Stars at Night Ballroom 2 - 3rd Level
3:45-5:15 p.m.	Workshop: Implementation of Genetic Testing in Breast Cancer Patients	<i>Alternative practical models for genetic services in the era of increased demand</i>	Banu Arun, M.D.	Stars at Night Ballroom 2 - 3rd Level
3:45-5:15 p.m.	Workshop: Conversations on Tough Topics Surrounding Cancer Care <i>Moderated by Susan Rafta</i>	<i>Challenging conversations: The toll on healthcare providers</i>	Sharon Giordano, M.D.	Stars at Night Ballroom 3 & 4 - 3rd Level

Wednesday, Dec. 11

8:45-11:15 a.m	General Session 1	<i>Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)</i>	Rashmi Murthy, M.D.	Hall 3
-----------------------	--------------------------	---	----------------------------	--------

Thursday, Dec. 12

7-9 a.m.	Spotlight Session 4	<i>Discussant for Spotlight Session 4 Targeting HER2 and DNA Repair</i>	Jennifer Litton, M.D.	Stars at Night Ballroom 1 & 2 - 3rd Level
1-2 p.m.	Case Discussion 1		Benjamin Smith, M.D.	Stars at Night Ballroom 1 & 2 - 3rd Level

3:15-5 p.m.	General Session 4	<i>Investigating genomic and phenotypic evolution of triple-negative breast cancer chemoresistance and metastasis in patient-derived xenografts</i>	Gloria Echeverria, Ph.D.	Hall 3
5-7 p.m.	Spotlight Session 6	<i>Local Regional Therapy/DCIS</i>	Karen Hoffman, M.D.	Hemisfair Ballroom - 3rd Level
5-7 p.m.	Spotlight Session 7	<i>The Science of ER Resistance and Emerging Clinical Strategies</i>	Stacy Moulder, M.D.	Stars at Night Ballroom 2 - 3rd Level
5-7 p.m.	Spotlight Session 7	<i>Discussant for The Science of ER Resistance and Emerging Clinical Strategies</i>	Rachel Layman, M.D.	Stars at Night Ballroom 2 - 3rd Level
Friday, Dec. 13				
9:45-11:30 a.m. (9:45 a.m.)	General Session 5	<i>Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis</i>	W. Fraser Symmans, M.D.	Hall 3
9:45-11:30 a.m. (10:30 a.m.)	General Session 5	<i>Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis</i>	Henry Kuerer, M.D.	Hall 3
1-2 p.m.	Case Discussion 2		W. Fraser Symmans, M.D.	Stars at Night Ballroom 1&2 - 3rd Level

P O S T E R P R E S E N T A T I O N S

Thursday, Dec. 12

7-9 a.m.	Poster Session 2	P2-09-04 Reclassification of variant of unknown significance in <i>BRCA1</i> and <i>BRCA2</i> genes based on loss of Heterozygosity assay	Banu Arun, M.D.	Hall 1
7-9 a.m.	Poster Session 2	P2-11-03: Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer	W. Fraser Symmans, M.D.	Hall 1
5-7 p.m.	Poster Session 3	P3-11-14: ONC201 synergistically induces cell death in triple-negative breast cancer with CDK 4/6 and MEK inhibition	Bora Lim, M.D.	Hall 1

Friday, Dec. 13

7-9 a.m.	Poster Session 4	P4-01-01: Circulating tumor cells detected after neoadjuvant therapy for inflammatory breast cancer are associated with early relapse despite pCR	Anthony Lucci, M.D.	Hall 1
----------	------------------	---	----------------------------	--------

5-7 p.m.	Poster Session 5	P5-14-03 (presenting on behalf of Arlene Chan first author): Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-Positive early-stage breast cancer: Phase II CONTROL trial.	Carlos Barcenas, M.D.	Hall 1
5-7 p.m.	Poster Session OT3	OT3-15-02: A randomized, double-blind, placebo-controlled study of 4-hydroxytamoxifen topical gel in women with mammographically dense breasts	Banu Arun, M.D.	Hall 1
Saturday, Dec. 14				
7-9 a.m.	Poster Session 6	P6-08-06: Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer	Banu Arun, M.D.	Hall 1
7-9 a.m.	Poster Session 6	P6-08-26: Clinical characteristics of breast cancer patients with ATM mutations	Banu Arun, M.D.	Hall 1